Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck & Co And Galapagos sign obesity and diabetes deal

This article was originally published in Scrip

Executive Summary

Merck & Cois to pay Galapagos€1.5 million up-front and up to €170 million in development and regulatory milestones for the rights to license obesity and diabetes drug candidates developed by the Belgian drug discovery company. Merck will have the exclusive option to develop in clinical trials and commercialise candidates discovered in Galapagos's SilenceSelect target discovery platform for identifying novel targets in obesity and diabetes. Galapagos will be responsible for the discovery and pre-clinical development of such treatments and may begin Phase I clinical studies. The company develop and commercialise any compounds for which Merck does not exercise its exclusive option. Merck may also pay sales milestones and royalties upon the commercialisation of any products developed in the agreement.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts